Strong knees and hips give leg-up to top-line for ortho companies
This article was originally published in Clinica
Abbott Labs' medical products division grew 14% in the first quarter of 2008, driven by sales of its diagnostic products, which increased 17% to $832m. Point-of-care and molecular diagnostics performed particularly strongly, growing 22% and 21%, respectively. Vascular sales, up 8% at $452m, were held back by a decline in the percutaneous coronary intervention market, resulting in lower third-party catheter sales. On the coronary stent side, sales increase 18% to $189m. Abbott said it still expects its Xience V drug-eluting stent (DES), already available internationally, to receive FDA approval in the second quarter of 2008.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.